Local Injection of Endothelin-1 Produces Pain-like Behavior and Excitation of Nociceptors in Rats
Overview
Affiliations
Neurobehavioral and neurophysiological actions of the peptide endothelin-1 (ET-1) were investigated after subcutaneous plantar hindpaw injections in adult male Sprague Dawley rats. Hindpaw flinching developed within minutes after ET-1 (8-16 nmol) injection, peaked at 30 min, lasted for 60 min, and was strongly inhibited by the endothelin-A (ET(A)) receptor antagonist, BQ-123 (3.2 m). In separate experiments, impulse activity of single, physiologically characterized sensory C-, Adelta-, and Abeta-fibers was recorded from the sciatic nerve in anesthetized rats after subcutaneous injections of endothelin-1 (1-20 nmol), alone or together with BQ-123 (3.2 m), into the plantar hindpaw receptive fields of these units. All nociceptive C-fibers (31 of 33 C-fibers studied) were excited by ET-1 (1-20 nmol) in a dose-dependent manner. For doses of 16-20 nmol, the mean latency for afferent activation after injection of ET-1 was 3.16 +/- 0.31 min, and the mean and maximum response frequency were 2.02 +/- 0.48 impulses (imp)/sec and 14.0 +/- 3.2 imp/sec, respectively. All 10 nociceptive Adelta-fibers (of 12 Adelta-fibers studied) also responded to 1-20 nmol of ET-1 in a dose-dependent manner with a mean latency of 3.5 +/- 0.12 min and mean response frequency of 3.3 +/- 2.3 imp/sec. In contrast, most Abeta-fibers (9 of 12) did not respond to ET-1. BQ-123, when coinjected with ET-1, blocked ET-1-induced activation in all C- and Adelta-fibers tested. These data demonstrate that subcutaneous administration of ET-1 to the rat plantar hindpaw produces pain-like behavior and selective excitation of nociceptive fibers through activation of ET(A) receptors.
Serum Endothelin-1 Level Can Reflect the Degree of Lumbar Degeneration: A Cross-Sectional Study.
Uslu E, Gulkesen A, Akgol G, Alkan G, Poyraz A, Ilhan N Cureus. 2024; 16(5):e59966.
PMID: 38854285 PMC: 11162144. DOI: 10.7759/cureus.59966.
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease.
Ivkovic V, Bruchfeld A Clin Kidney J. 2024; 17(4):sfae072.
PMID: 38660120 PMC: 11040512. DOI: 10.1093/ckj/sfae072.
Mavridis T, Mavridi A, Karampela E, Galanos A, Gkiokas G, Iacovidou N Neurocrit Care. 2024; 41(2):455-468.
PMID: 38443708 DOI: 10.1007/s12028-024-01950-2.
Albrecht P, Liu Y, Houk G, Ruggiero B, Banov D, Dockum M Pain Rep. 2024; 9(2):e1119.
PMID: 38375092 PMC: 10876238. DOI: 10.1097/PR9.0000000000001121.
Macharia J, Raposa B, Sipos D, Melczer C, Toth Z, Kaposztas Z Healthcare (Basel). 2023; 11(22).
PMID: 37998446 PMC: 10671794. DOI: 10.3390/healthcare11222954.